Esomeprazole potassium salt
Based on 2 publication(s) in Google Scholar
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H+, K+-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.98%
- CAS 番号: 161796-84-5
- 分子式: C17H18KN3O3S
- 分子量:383.51
-
保管条件:
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-B0656
RabeprazolePump Inhibitor -
HY-17023
Esomeprazole sodiumProton Pump Inhibitor -
HY-13662
LansoprazoleProton Pump Inhibitor -
HY-17507
PantoprazoleProton Pump Inhibitor -
HY-101664
IlaprazoleProton Pump Inhibitor -
HY-B0656A
Rabeprazole sodiumPump Inhibitor -
HY-13662A
Lansoprazole sodium -
HY-101427
BamaquimastAnti-asthmatic Agent -
HY-B2145
Ilaprazole sodiumProton Pump Inhibitor -
HY-109079
AbeprazanProton Pump/Potassium-competitive Acid Inhibitor -
HY-100007
VonoprazanPotassium-Competitive Acid Blocker -
HY-B1446
Esomeprazole magnesiumH+, K+-ATPase Inhibitor
MedChemExpress（MCE）の使用を引用している文献 Esomeprazole potassium salt
More
生物活性
製品説明
IC50 & Target
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
>10 μM
Compound: 92309092
|
HARVARD: Cytotoxicity in HepG2 cell line
HARVARD: Cytotoxicity in HepG2 cell line
|
[PMID: 22586124] |
| HepG2 | IC50 |
0.291 μM
Compound: 92309092
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
|
[PMID: 22586124] |
体外実験
Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
-
Cell Line:MDA-MB-468 cells
-
Concentration:25 µM, 50 µM, 75 µM, 100 µM
-
Incubation Time:20 hours
-
Result:Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury[2]
-
Dosage:30 mg/kg, 300 mg/kg
-
Administration:Oral gavage; daily; for 19 or 11 days
-
Result:Significantly inhibited the progression of fibrosis throughout the lungs of the animals.
化学情報
-
CAS 番号 161796-84-5
-
性状 Solid
-
分子量 383.51
-
分子式 C17H18KN3O3S
-
Color White to light yellow
-
SMILES
O=[S@](C1=NC2=CC=C(OC)C=C2[N-]1)CC3=NC=C(C)C(OC)=C3C.[K+]
-
別名
(S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
-20°C, protect from light, stored under nitrogen
* The compound is unstable in solutions, freshly prepared is recommended.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
Inhibition of iron ion accumulation alleviates polystyrene nanoplastics-induced pulmonary fibroblast proliferation and activation. [Abstract]2025 Oct 30:164:115367. PMID: 40811949 -
溶剤 & 溶解度
体外:
DMSO : 33.33 mg/mL (86.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. [Content Brief]
[2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. [Content Brief]
[3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6075 mL | 13.0375 mL | 26.0749 mL | 65.1873 mL |
| 5 mM | 0.5215 mL | 2.6075 mL | 5.2150 mL | 13.0375 mL | |
| 10 mM | 0.2607 mL | 1.3037 mL | 2.6075 mL | 6.5187 mL | |
| 15 mM | 0.1738 mL | 0.8692 mL | 1.7383 mL | 4.3458 mL | |
| 20 mM | 0.1304 mL | 0.6519 mL | 1.3037 mL | 3.2594 mL | |
| 25 mM | 0.1043 mL | 0.5215 mL | 1.0430 mL | 2.6075 mL | |
| 30 mM | 0.0869 mL | 0.4346 mL | 0.8692 mL | 2.1729 mL | |
| 40 mM | 0.0652 mL | 0.3259 mL | 0.6519 mL | 1.6297 mL | |
| 50 mM | 0.0521 mL | 0.2607 mL | 0.5215 mL | 1.3037 mL | |
| 60 mM | 0.0435 mL | 0.2173 mL | 0.4346 mL | 1.0865 mL | |
| 80 mM | 0.0326 mL | 0.1630 mL | 0.3259 mL | 0.8148 mL |
Esomeprazole potassium salt 関連分類
HY-17021B 関連分類
Powered by Bioz